DNA X, Inc.
For the period ended Mar 31, 2026. Filed May 20, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 20, 2026
SONM$2.35+5.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Cash flows from combined continuing and discontinued operations: | ||
| Cash flows from operating activities: | ||
| Net loss | $6,340 | $458 |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Gain on sale of assets, net assets transferred | (15,563) | — |
| Depreciation and amortization | — | 1,055 |
| Amortization of debt discount and issuance costs | 43 | 41 |
| Stock-based compensation ($211 from continuing and $93 from discontinued operations for 2026 and all from discontinued operations for 2025-see Note 7) | 304 | 290 |
| Loss on remeasurement of derivative liability | 227 | — |
| Release of customer allowance liability | — | (5,271) |
| Investment income from DNA X LLC under the equity method | (48) | — |
| Other | — | (97) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 250 | (649) |
| Non-trade receivable | — | 667 |
| Inventory | 5,490 | 2,255 |
| Prepaid expenses and other current assets | 1,663 | (127) |
| Contract fulfilment assets | 129 | (2,548) |
| Other assets | (103) | (3) |
| Accounts payable | (2,653) | (5,554) |
| Accrued liabilities | (1,288) | (218) |
| Deferred tax assets | 1,364 | — |
| Deferred tax liabilities | 600 | — |
| Income tax payable | (221) | 95 |
| Net cash used in operating activities | (3,466) | (9,606) |
| Cash flows from investing activities: | ||
| Net cash received from sale of assets | 3,358 | — |
| Net cash provided by investing activities | 3,358 | — |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of issuance costs | — | 3,537 |
| Proceeds from promissory note, net of issuance costs | — | 2,790 |
| Proceeds from short-term borrowings | — | 51 |
| Net cash provided by financing activities | — | 6,378 |
| Net decrease in cash and cash equivalents | (108) | (3,228) |
| Cash and cash equivalents at beginning of period | 1,303 | 5,343 |
| Cash and cash equivalents at end of period | $1,195 | $2,115 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $257 | $20 |
| Cash paid for income taxes | $— | $12 |
| Supplemental disclosure of non-cash activities: | ||
| Repayment of notes payable from proceeds of asset sale | $5,476 | $— |
| Receivable for cash held back from asset sale | $1,500 | $— |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements*.*
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.